|Jmol-3D images||Image 1|
|Molar mass||203.20 g mol−1|
| (what is: / ?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Norfenfluramine, or 3-trifluoromethylamphetamine, is a drug of the amphetamine family which behaves as a serotonin and norepinephrine releasing agent and potent 5-HT2A, 5-HT2B, and 5-HT2C agonist. The action of norfenfluramine on 5-HT2B receptors on heart valves leads to a characteristic pattern of heart failure following proliferation of cardiac fibroblasts on the tricuspid valve, known as cardiac fibrosis. This side effect led to the withdrawal of fenfluramine as an anorectic agent worldwide, and to the withdrawal of benfluorex in Europe, as both fenfluramine and benfluorex form norfenfluramine as an active metabolite.
- Setola, V.; Dukat, M.; Glennon, R. A.; Roth, B. L. (2005). "Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor" (pdf). Molecular Pharmacology 68 (1): 20–33. doi:10.1124/mol.104.009266. PMID 15831837.
- "European Medicines Agency recommends withdrawal of benfluorex from the market in European Union" (pdf). European Medicines Agency. 2009-12-18.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|